8-K ·Filed Aug 19, 2026

BAX

BAXTER INTERNATIONAL INC
NEUTRAL
Impact 3/10
Horizonweeks Processed1mo ago SEC0001193125-26-356188
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor the Q3 2026 earnings release for any changes to the full-year 2026 outlook under the new CFO. The leadership transition is orderly and not a catalyst for near-term trading.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
BAX ▼ -13.59% at T+20d
NEUTRAL call ✗ call lost -13.59% · α vs SPY -11.64% · entry $26.64 → $23.02
Next anchor: T+60d in 6w
Latest observation: T+29 -9.85% FF3 residual α
Entry anchored
Aug 19, 07:45 AM ET
via 1-min bar
T+1d
-0.86%
call -0.86% · α -0.02%
$26.41
settled 6w ago
T+5d
-0.53%
call -0.53% · α -0.14%
$26.50
settled 5w ago
T+20d
-13.59%
call -13.59% · α -11.64%
$23.02
settled 15d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Baxter appointed John Rogers as CFO, effective October 1, 2026, replacing departing interim CFO Anita Zielinski. The company also reiterated its full-year 2026 financial outlook. This is a routine leadership transition with no new financial information, making it a neutral event for the stock.

Key Facts

  • John Rogers appointed EVP and CFO, effective October 1, 2026.
  • Rogers joins from Smith+Nephew plc, where he served as CFO.
  • Interim CFO Anita Zielinski departs September 15, 2026; CEO Andrew Hider will serve as interim CFO for a two-week period.
  • Bernie Heine appointed interim CAO and Controller.
  • Baxter reiterated its full-year 2026 financial outlook.
  • New CFO compensation includes $925,000 base salary, 100% target bonus, $4M annual equity target, and a $2.8M sign-on bonus.

Financial Impact

No new financial data provided; full-year 2026 outlook reiterated from July 30, 2026 earnings.

Risk Factors

  • Execution risk on Baxter's turnaround strategy under new CFO.
  • Potential for future guidance revision if the new CFO reassesses the financial plan.

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
25% bullish (20 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-356188
Document: d154782dex101.htm0001193125-26-356188
Document: d154782dex991.htm0001193125-26-356188
Document: 0001193125-26-356188-index-headers.html0001193125-26-356188
Document: 0001193125-26-356188-index.html0001193125-26-356188
Document: 0001193125-26-356188.txt0001193125-26-356188
12 reports for BAX
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+5▲ +5.37%Jun 11, 2026
Filters
Rows
Reports for BAX — sortable, filterable
TypeNow
Aug 19, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$26.64 $23.02▼ −13.59%▼ −11.64%$23.52 (−11.71%)
Aug 18, 2026
6w ago
8-K
MIXED ★ 5/10
$26.64 $23.02▼ −13.59%▼ −11.64%$23.52 (−11.71%)
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 4/10
$26.95 $24.18▼ −10.28%▼ −8.38%$23.52 (−12.73%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$28.35 $25.48▼ −10.12%▼ −8.89%$23.52 (−17.04%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 7/10
$26.75 $25.93▼ −3.07%▼ −7.03%$23.52 (−12.07%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 6/10
$20.49 $22.46▼ −9.61%▼ −7.72%$23.52 (−14.79%)
May 8, 2026
20w ago
8-K
NEUTRAL ★ 2/10
$17.53 $20.03▲ +14.26%▲ +14.57%$23.52 (+34.17%)
Apr 30, 2026
22w ago
8-K
MIXED ★ 5/10
$17.58 $19.25▲ +9.50%▲ +4.53%$23.52 (+33.79%)
Apr 29, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$16.90 $19.33▲ +14.38%▲ +8.92%$23.52 (+39.17%)
Mar 23, 2026
27w ago
DEFA14A
NEUTRAL ★ 2/10
$16.61 $18.49▲ +11.32%▲ +3.90%$23.52 (+41.60%)
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access